Semaglutide 2.4 mg at Asian BMI thresholds

Design

Phase 3b, randomised, double-blind, placebo-controlled, 2:1 allocation

Population

242 adults in China and Taiwan with overweight or obesity at local BMI thresholds; 19% with type 2 diabetes

Primary outcome

Percentage weight change and proportion reaching at least 5% loss at 44 weeks

Effect

-12.1% vs -2.2%; difference -9.9 points (95% CI -11.8 to -8.0); 5% loss 80.5% vs 24.4%

A phase 3b, double-blind trial (STEP 12) randomised 242 adults in mainland China and Taiwan 2:1 to once-weekly semaglutide 2.4 mg or placebo, each with lifestyle support, for 44 weeks. Entry used locally defined cut-offs, a BMI of 24 to under 28 with a weight-related comorbidity, or 28 to under 30, so the population sat well below the BMI 30 threshold most Western obesity trials use. About a fifth had type 2 diabetes.

Weight fell 12.1% with semaglutide against 2.2% with placebo, a difference of 9.9 percentage points, and 80.5% reached at least 5% loss versus 24.4%. The effect size matches what the drug delivers in higher-BMI Western cohorts, which matters because Asian populations carry cardiometabolic risk at lower BMI and have been under-represented in the registration trials.

For Indian practice the signal is that the lower entry thresholds used here sit closer to the adiposity-linked risk seen locally than the BMI 30 rule. Availability and cost, not efficacy, remain the limiting step. Gastrointestinal effects were the commonest adverse events, as expected, and dose titration still applies.

• Entry was a BMI of 24 to under 28 with a comorbidity, or 28 to under 30, below the usual obesity-trial cut-off.
• Mean weight loss was 12.1% with semaglutide versus 2.2% with placebo over 44 weeks.
• Four in five reached at least 5% weight loss, against about one in four on placebo.
• Gastrointestinal symptoms were the most common adverse events; titrate the dose and counsel on them.
• Cost and access, not efficacy, are the limiting factor for most Indian patients.

Why it matters

It extends the obesity-trial evidence to the lower BMI thresholds that better fit Asian cardiometabolic risk.

Don't overread it

This measured weight and safety over 44 weeks, not cardiovascular or other hard outcomes.

The statistics, in plain English

The 9.9-percentage-point gap is both statistically and clinically large, and its confidence interval (-11.8 to -8.0) stays well away from zero. The odds ratio of 14.8 for reaching 5% loss is inflated by how few placebo patients got there, so read it as a large effect rather than a precise multiplier.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.